Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer's and Parkinson's diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington's disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases; Roche to develop therapeutics for the treatment of complement-mediated diseases; and drug research collaboration with SRI International for the intracellular delivery of nucleic acid-based drugs, as well as a research collaboration agreement with Cerveau Technologies, Inc. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone760-931-9200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$599.67 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/3/2019 (Estimated)
OptionableOptionable
Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions
What is Ionis Pharmaceuticals' stock symbol?
Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."
How were Ionis Pharmaceuticals' earnings last quarter?
Ionis Pharmaceuticals Inc (NASDAQ:IONS) posted its quarterly earnings results on Wednesday, February, 27th. The company reported $2.21 EPS for the quarter, beating the consensus estimate of $0.01 by $2.20. The firm earned $192 million during the quarter, compared to analysts' expectations of $159.59 million. Ionis Pharmaceuticals had a return on equity of 41.89% and a net margin of 45.64%. The business's revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter last year, the firm earned ($0.03) earnings per share. View Ionis Pharmaceuticals' Earnings History.
When is Ionis Pharmaceuticals' next earnings date?
What guidance has Ionis Pharmaceuticals issued on next quarter's earnings?
Ionis Pharmaceuticals updated its FY 2019 earnings guidance on Wednesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $725 million, compared to the consensus revenue estimate of $816.4 million.
What price target have analysts set for IONS?
7 brokers have issued 12-month price objectives for Ionis Pharmaceuticals' stock. Their predictions range from $48.00 to $82.00. On average, they anticipate Ionis Pharmaceuticals' stock price to reach $61.8571 in the next year. This suggests that the stock has a possible downside of 21.6%. View Analyst Price Targets for Ionis Pharmaceuticals.
What is the consensus analysts' recommendation for Ionis Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 1 sell rating, 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ionis Pharmaceuticals.
Has Ionis Pharmaceuticals been receiving favorable news coverage?
Headlines about IONS stock have been trending positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ionis Pharmaceuticals earned a daily sentiment score of 2.1 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the near future.
Who are some of Ionis Pharmaceuticals' key competitors?
Some companies that are related to Ionis Pharmaceuticals include Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TAK), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Mylan (MYL), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF) and Alnylam Pharmaceuticals (ALNY).
What other stocks do shareholders of Ionis Pharmaceuticals own?
Who are Ionis Pharmaceuticals' key executives?
Ionis Pharmaceuticals' management team includes the folowing people:
- Dr. Stanley T. Crooke, Founder, Exec. Chairman, CEO & Pres (Age 74)
- Dr. Brett P. Monia, Founder, COO & Sr. VP of Translational Medicine (Age 58)
- Ms. Elizabeth L. Hougen, CFO & Sr. VP of Fin. (Age 57)
- Dr. Richard S. Geary Ph.D., Sr. VP of Devel. (Age 61)
- Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 65)
Who are Ionis Pharmaceuticals' major shareholders?
Ionis Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (14.91%), Baillie Gifford & Co. (6.36%), BB Biotech AG (6.35%), BlackRock Inc. (5.58%), First Trust Advisors LP (1.61%) and American Century Companies Inc. (1.17%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Ionis Pharmaceuticals Inc, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce, Spencer R Berthelsen and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.
Which institutional investors are selling Ionis Pharmaceuticals stock?
IONS stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Pinnacle Associates Ltd., Tocqueville Asset Management L.P., Millennium Management LLC, Los Angeles Capital Management & Equity Research Inc., Raymond James & Associates, Stifel Financial Corp and California Public Employees Retirement System. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.
Which institutional investors are buying Ionis Pharmaceuticals stock?
IONS stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, American Century Companies Inc., Two Sigma Advisers LP, D. E. Shaw & Co. Inc., BlackRock Inc., Two Sigma Investments LP, First Trust Advisors LP and Geode Capital Management LLC. View Insider Buying and Selling for Ionis Pharmaceuticals.
How do I buy shares of Ionis Pharmaceuticals?
Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ionis Pharmaceuticals' stock price today?
One share of IONS stock can currently be purchased for approximately $78.90.
How big of a company is Ionis Pharmaceuticals?
Ionis Pharmaceuticals has a market capitalization of $10.92 billion and generates $599.67 million in revenue each year. The company earns $273.74 million in net income (profit) each year or $2.96 on an earnings per share basis.
What is Ionis Pharmaceuticals' official website?
How can I contact Ionis Pharmaceuticals?
Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.
MarketBeat Community Rating for Ionis Pharmaceuticals (NASDAQ IONS)
MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days.
